MRM
GHDX

Michael R. Murphy’s Genomic Health, Inc. GHDX Stock Holding History

Michael R. Murphy’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-291,292
Closed -$8.25M – 22
2014
Q3 		$8.25M Buy
+291,292
New +$8.12M 2.85% 17

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael R. Murphy's GHDX Position: Q4 2014 in Review

Michael R. Murphy sold out of Genomic Health, Inc. (GHDX) in Q4 2014, closing a stake of 291,292 shares — an estimated $8.25M sold.

Michael R. Murphy first reported a position in GHDX in Q3 2014 and held it in 1 quarter. The position peaked at $8.25M in Q3 2014. 113 funds tracked by Wall St. Rank hold GHDX as of Q4 2014.

  • Michael R. Murphy reported no remaining Genomic Health, Inc. position as of Q4 2014 after selling out during the quarter.
  • Michael R. Murphy sold 291,292 Genomic Health, Inc. shares in Q4 2014, an estimated $8.25M.
  • Michael R. Murphy first reported a position in Genomic Health, Inc. in Q3 2014 and held it in 1 quarter.
  • Michael R. Murphy's Genomic Health, Inc. position peaked at $8.25M in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2014.

Based on Michael R. Murphy's 13F filing for Q4 2014, filed 13 Feb 2015.